|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
Cytomx Therapeutics, Inc. (CTMX) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
65,160,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0 - $0 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile CytomX Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company. Co. is developing an antibody-based therapeutics created using its Probody® therapeutic technology platform. Co.'s products include: Praluzatamab ravtansine, which is an activated antibody-drug conjugates directed against CD166, a tumor target previously considered undruggable due to its high expression on normal tissues; CX-2029, which opens a therapeutic window for targeting CD71; Pacmilimab, which is a Probody therapeutic against PD-L1, a clinically and commercially validated cancer target; and BMS-986249 and BMS-986288, which is the Probody versions of ipilimumab.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
47,819 |
75,591 |
103,916 |
162,805 |
Total Sell Value |
$99,726 |
$138,068 |
$174,902 |
$267,502 |
Total People Sold |
5 |
5 |
5 |
8 |
Total Sell Transactions |
5 |
10 |
14 |
26 |
End Date |
2023-12-28 |
2023-09-26 |
2023-03-28 |
2022-03-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Belvin Marcia |
SVP, Chief Scientific Officer |
|
2023-03-22 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
80,820 |
|
- |
|
Belvin Marcia |
SVP, Chief Scientific Officer |
|
2023-03-22 |
4 |
A |
$0.00 |
$0 |
D/D |
60,000 |
140,820 |
|
- |
|
Ogden Christopher |
SVP, Finance and Accounting |
|
2023-03-16 |
4 |
S |
$1.98 |
$1,021 |
D/D |
(516) |
37,772 |
|
- |
|
Campoy Carlos |
Chief Financial Officer |
|
2023-03-16 |
4 |
S |
$1.98 |
$3,459 |
D/D |
(1,748) |
38,224 |
|
- |
|
Landau Jeffrey B |
Chief Financial Officer |
|
2023-03-16 |
4 |
S |
$1.98 |
$2,923 |
D/D |
(1,477) |
69,248 |
|
- |
|
Mccarthy Sean A. |
CEO |
|
2023-03-16 |
4 |
S |
$1.88 |
$13,391 |
D/D |
(7,121) |
388,821 |
|
- |
|
Rowland Lloyd A |
General Counsel |
|
2023-03-16 |
4 |
S |
$1.98 |
$4,031 |
D/D |
(2,037) |
71,095 |
|
- |
|
Peterson Amy C. |
EVP, Chief Development Officer |
|
2023-03-16 |
4 |
S |
$1.98 |
$8,425 |
D/D |
(4,257) |
58,433 |
|
- |
|
Landau Jeffrey B |
Chief Business Officer |
|
2023-02-02 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
70,725 |
|
- |
|
Rowland Lloyd A |
General Counsel |
|
2023-02-02 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
73,132 |
|
- |
|
Mccarthy Sean A. |
CEO |
|
2023-02-02 |
4 |
A |
$0.00 |
$0 |
D/D |
105,000 |
395,942 |
|
- |
|
Ogden Christopher |
SVP, Finance and Accounting |
|
2023-02-02 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
38,288 |
|
- |
|
Rowland Lloyd A |
General Counsel |
|
2022-07-20 |
4 |
S |
$1.42 |
$7,968 |
D/D |
(5,602) |
43,689 |
|
- |
|
Campoy Carlos |
Chief Financial Officer |
|
2022-07-20 |
4 |
S |
$1.42 |
$5,617 |
D/D |
(3,949) |
39,972 |
|
- |
|
Landau Jeffrey B |
Chief Business Officer |
|
2022-07-20 |
4 |
S |
$1.42 |
$5,982 |
D/D |
(4,206) |
30,725 |
|
- |
|
Peterson Amy C. |
EVP, Chief Development Officer |
|
2022-07-20 |
4 |
S |
$1.42 |
$10,612 |
D/D |
(7,463) |
62,690 |
|
- |
|
Hannah Alison L. |
Chief Medical Officer |
|
2022-07-20 |
4 |
S |
$1.42 |
$7,965 |
D/D |
(5,602) |
31,898 |
|
- |
|
Mccarthy Sean A. |
President and CEO |
|
2022-07-20 |
4 |
S |
$1.42 |
$21,206 |
D/D |
(14,911) |
290,942 |
|
- |
|
Rowland Lloyd A |
General Counsel |
|
2022-07-19 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
49,291 |
|
- |
|
Campoy Carlos |
Chief Financial Officer |
|
2022-07-19 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
43,921 |
|
- |
|
Landau Jeffrey B |
Chief Business Officer |
|
2022-07-19 |
4 |
A |
$0.00 |
$0 |
D/D |
11,250 |
34,931 |
|
- |
|
Peterson Amy C. |
EVP, Chief Development Officer |
|
2022-07-19 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
70,153 |
|
- |
|
Hannah Alison L. |
Chief Medical Officer |
|
2022-07-19 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
37,500 |
|
- |
|
Mccarthy Sean A. |
President and CEO |
|
2022-07-19 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
305,853 |
|
- |
|
Mccarthy Sean A. |
President and CEO |
|
2022-05-09 |
4 |
OE |
$0.95 |
$85,930 |
D/D |
90,931 |
265,853 |
|
- |
|
38 Records found
|
|
Page 1 of 2 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|